EBSAM
PFE icon

Eubel Brady & Suttman Asset Management’s Pfizer PFE Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,147
Closed -$299K – 94
2023
Q2 		$299K Buy
8,147
+27
+0.3% +$1.05K 0.04% 76
2023
Q1 		$331K Buy
8,120
+12
+0.1% +$518 0.05% 76
2022
Q4 		$415K Buy
8,108
+107
+1% +$5.13K 0.07% 76
2022
Q3 		$350K Hold
8,001
– – 0.06% 73
2022
Q2 		$419K Hold
8,001
– – 0.08% 59
2022
Q1 		$414K Hold
8,001
– – 0.08% 59
2021
Q4 		$472K Hold
8,001
– – 0.09% 58
2021
Q3 		$344K Hold
8,001
– – 0.07% 56
2021
Q2 		$290K Sell
8,001
-8,001
-50% -$311K 0.03% 165
2021
Q1 		$580K Buy
16,002
+9,601
+150% +$341K 0.06% 70
2020
Q4 		$236K Sell
6,401
-346
-5% -$12.7K 0.06% 71
2020
Q3 		$235K Hold
6,747
– – 0.06% 66
2020
Q2 		$209K Hold
6,747
– – 0.05% 71
2020
Q1 		$209K Hold
6,747
– – 0.06% 68
2019
Q4 		$251K Buy
6,747
+58
+0.9% +$2.07K 0.07% 69
2019
Q3 		$228K Buy
6,689
+8
+0.1% +$291 0.07% 69
2019
Q2 		$275K Buy
6,681
+6
+0.1% +$238 0.08% 64
2019
Q1 		$269K Buy
6,675
+6
+0.1% +$240 0.08% 61
2018
Q4 		$276K Buy
6,669
+16
+0.2% +$664 0.09% 59
2018
Q3 		$278K Buy
6,653
+6
+0.1% +$231 0.08% 62
2018
Q2 		$229K Sell
6,647
-8
-0.1% -$273 0.07% 63
2018
Q1 		$224K Buy
6,655
+7
+0.1% +$241 0.07% 60
2017
Q4 		$228K Sell
6,648
-23
-0.3% -$784 0.07% 68
2017
Q3 		$226K Buy
6,671
+35
+0.5% +$1.13K 0.07% 72
2017
Q2 		$211K Buy
6,636
+6
+0.1% +$189 0.06% 73
2017
Q1 		$215K Buy
6,630
+56
+0.9% +$1.77K 0.06% 69
2016
Q4 		$203K Buy
6,574
+7
+0.1% +$214 0.06% 72
2016
Q3 		$211K Sell
6,567
-5
-0.1% -$167 0.07% 74
2016
Q2 		$220K Buy
+6,572
New +$210K 0.07% 69

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's PFE Position: Q3 2023 in Review

Eubel Brady & Suttman Asset Management sold out of Pfizer (PFE) in Q3 2023, closing a stake of 8,147 shares — an estimated $299K sold.

Eubel Brady & Suttman Asset Management first reported a position in PFE in Q2 2016 and held it in 29 quarters. The position peaked at $580K in Q1 2021. 2,928 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

  • Eubel Brady & Suttman Asset Management reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 8,147 Pfizer shares in Q3 2023, an estimated $299K.
  • Eubel Brady & Suttman Asset Management first reported a position in Pfizer in Q2 2016 and held it in 29 quarters.
  • Eubel Brady & Suttman Asset Management's Pfizer position peaked at $580K in Q1 2021.
  • 2,928 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.